Dr. Rachel M Hayward Arad, PHD Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 155 Airport Rd, Fitchberg, MA 01420 Phone: 978-343-6300 |
News Archive
PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.
pSivida Corp. has announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change.
XenoPort, Inc. announced today that it will present data on a new preclinical product candidate, XP23829, at the upcoming 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Gothenburg, Sweden, October 13 - 16, 2010.
OXIS International, today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX joint health formula, launched commercially in December 2010.
› Verified 1 days ago